论文部分内容阅读
目的应用蛋白质组技术探讨首次持续完全缓解(CCR_1)时间相差显著的急性髓系白血病(AML-M_2a)患者诱导治疗前及其复发患者的白血病细胞蛋白质差异表达与预后的关系。方法将提取的17例 AML-M_2a 患者首次诱导缓解前的骨髓单个核细胞按正规化疗后 CDR_1时间分组,大于12个月为 A 组(11例),小于6个月者为 B 组(6例),B 组患者有3例在复发时的骨髓单个核细胞为 C 组。运用双向电泳技术对 A、B、C3组白血病细胞蛋白质进行分离,对部分差异蛋白利用基质辅助激光解吸电离飞行时间质量光谱法(matrix-assisted laser desorption-ionization time-of-flight inassspectrometry,MALDI-TOF-MS)进行鉴定。结果 A 组与 B 组比较,质谱鉴定了6个差异蛋白质,分别为微管蛋白特定分子伴侣 B、髓过氧化物酶、转胶蛋白2CH 结构域、谷胱苷肽 S-转移酶、锌酯蛋白、3-磷酸甘油醛脱氢酶;C 组为3例自身对照比较,质谱鉴定了3个差异蛋白质,分别为 NAD(P)H、HES_1、假定蛋白。结论 AML-M_2a 患者诱导缓解治疗前的白血病细胞差异蛋白质表达水平与其预后有关,白血病复发时骨髓细胞蛋白质有变化。
Objective To investigate the relationship between protein differential expression and prognosis of leukemia cells in patients with acute myeloid leukemia (AML-M_2a) who had the first continuous complete remission (CCR_1) time difference before and after induction therapy. Methods The 17 cases of AML-M_2a were recruited for the first time to induce bone marrow mononuclear cells of pre-remission grouping according to CDR_1 time after formal chemotherapy. Group A (11 cases) was more than 12 months and group B was less than 6 months ), B group of patients in 3 cases of bone marrow mononuclear cells in the recurrence of the C group. Proteins from A, B and C3 leukemia cells were separated by two-dimensional gel electrophoresis. Some of the differentially expressed proteins were analyzed by matrix-assisted laser desorption-ionization time-of-flight inasspectrometry (MALDI-TOF -MS). Results Compared with group B, six differential proteins were identified by mass spectrometry in group A, which were tubulin-specific chaperone B, myeloperoxidase, gelatinase 2CH domain, glutathione S-transferase, zinc ester Protein, glyceraldehyde-3-phosphate dehydrogenase; C group was compared with 3 self-control, identified three different proteins by mass spectrometry, NAD (P) H, HES_1, hypothetical protein. Conclusions The differential protein expression of leukemic cells before induction of remission therapy in AML-M 2 a patients is related to the prognosis of leukemia cells. The protein of bone marrow cells changes when leukemia recurred.